Skip to main content Skip to search Skip to main navigation

PANGEA XV: Worldwide Campaign against Falsified and Illegally Imported Medicinal Products

From 23 to 30 June 2022, Interpol conducted its 15th globally coordinated operation PANGEA against the illegal online trade of medicines. From fake COVID-19 tests to doping substances or narcotics, the range of illegal shipments was broad.

This year, 94 countries were involved in the operation. A total of more than 3 million units were seized worldwide, including more than 7,800 illegal and counterfeit medicines and medical products. The found counterfeit medicines were mostly produced in Asian countries with counterfeit erectile stimulants originating in India.

During the week, law enforcement

  • Investigated more than 4,000 web links, mainly from social media platforms and messaging apps
  • Shut down or removed more than 4,000 web links containing adverts for illicit products
  • Inspected nearly 3,000 packages and 280 postal hubs at airports, borders and mail distribution or cargo mail centres
  • Opened more than 600 new investigations and issued more than 200 search warrants

While results are still coming in from countries, enforcement actions have already disrupted the activities of at least 36 organized crime groups.

About 40 % of all products seized were counterfeit or unapproved erectile stimulants. Law enforcement agencies in Australia, Argentina, Malaysia, and the United States also seized more than 317,000 unapproved COVID-19 test kits. The seizures in the US alone have an estimated value of nearly USD 3 million.

If you are interested in more information on the global action please click here.


Source:

Interpol: PANGEA XV

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

ANVISA: Expands Recognition of Foreign GMP Authorities

ANVISA: Expands Recognition of Foreign GMP Authorities

Brazilian health authority ANVISA has updated the requirements for the recognition of Equivalent Foreign Regulatory Authorities (AREE) and the administrative procedures for Good Manufacturing Practice (GMP) certification (CBPF) through Normative Instruction IN 451/2026. The aim is to streamline and accelerate regulatory processes.
Read more
EDQM: Guidance on Reporting on Disappearances of Medicinal Products

EDQM: Guidance on Reporting on Disappearances of Medicinal Products

The EDQM has published guidance supporting the implementation of Recommendation CM/Rec(2024)3 on reporting medicinal products that disappear from the legal supply chain due to theft, loss or diversion. The initiative follows a European survey that identified shortcomings in reporting and co-ordination of such incidents.

Read more
Damage Control: Complaints and Recalls

Damage Control: Complaints and Recalls

Complaint handling and product recalls are important components of the Pharmaceutical Quality System (PQS). They serve to identify defective medicinal products and ensure that appropriate measures are taken to protect patient safety, as required by law and the competent supervisory authority.

Read more
What are the Phases of a Working Cycle During a Steam Sterilisation Process?

What are the Phases of a Working Cycle During a Steam Sterilisation Process?

Here's the answer:
Read more
EMA: 9 New Nitrosamines for Appendix 1

EMA: 9 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.
Read more
EMA: Reduced Testing of Incoming Starting Materials is a GMP Matter

EMA: Reduced Testing of Incoming Starting Materials is a GMP Matter

The European Medicines Agency (EMA) published an update to its “Quality of Medicines: Questions and Answers – Part 2”. The revision concerns the section on “Reduced testing of incoming starting materials”.
Read more
Previous
Next